Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms: early-phase trial registry
50 of 160 indexed Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #68 of 28,707 conditions by registered trial count.
160 US clinical trials · 50 currently recruiting · #68 of 28,707 conditions by registered trial count
Neoplasms: 160 US clinical trials tracked, 50 recruiting.
Neoplasms is the subject of 160 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 15 of these trials.
Enrollment posture brief
Registry condition neoplasms
OPEN 50 | RECR 31% | LATE 9 | EARLY 99 | RANK #68 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Aortic Valve Disease (31% recruiting · 16 trials)
Neoplasms lists 50 open slots (31% of 160 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms is recruiting below its size-band peers.
50 of 160 indexed trials (31.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neoplasms trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 15 of 160 trials (9.4%). 85 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasms enrolment sits around 81 participants.
Median target enrolment is 81 among the 159 trials that report a genuine target (sentinel values excluded). 87 of those (54.7%) plan for fewer than 100 participants.
-
Neoplasms research is mostly interventional.
130 interventional and 30 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
160 total, page 3 of 4
Genetic Exploration of the Molecular Basis of Malignancy in Adults
Sanford Health
NCT02416518
Biomarkers For Immune Checkpoint Inhibitors
Rhode Island Hospital
NCT04204434
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Pfizer
NCT00454649
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis Pharmaceuticals
NCT02077933
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Bayer
NCT01915576
Collection of Blood, Bone Marrow, Tumor or Tissue Samples
National Cancer Institute (NCI)
NCT00043615
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Pfizer
NCT00141297
Physical Activity and Healthy Eating Among Young Adult Cancer Survivors
UNC Lineberger Comprehensive Cancer Center
NCT05887401
An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection
National Cancer Institute (NCI)
NCT01445145
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
Mayo Clinic
NCT01471756
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Merck Sharp & Dohme
NCT05514444
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
Bayer
NCT01392521
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology
NCT00838539
Expressive Helping for Chinese-Speaking Cancer Patients and Survivors
New York University
NCT03945734
Comparing Aerobic to Resistance Training in Recovery From Cancer
TriService Nursing Research Program
NCT00237926
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
City of Hope Medical Center
NCT00359606
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Adherex Technologies
NCT00421811
Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study
St. Jude Children's Research Hospital
NCT02429063
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00161642
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02723864
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
NCT00599924
Indocyanine Green for Solid Tumors
University of Pennsylvania
NCT02280954
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Threshold Pharmaceuticals
NCT00102752
The Families Addressing Cancer Together Intervention for Parents With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05377749
Genotoxicity Assessment for Patients Undergoing Radiation Treatment
Yuhchyau Chen
NCT00167427
Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
National Institute of Dental and Craniofacial Research (NIDCR)
NCT00099762
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
Eli Lilly and Company
NCT01288989
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
Pfizer
NCT00511849
A Study Of PF-03732010 In Patients With Advanced Solid Tumors
Pfizer
NCT00557505
Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer
GlaxoSmithKline
NCT03336567
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development
NCT03926013
Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer
INSYS Therapeutics
NCT00046540
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
University of Vermont
NCT01524653
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Advanced Accelerator Applications
NCT03872778
Cancer Vaccine Targeting Brachyury Protein in Tumors
National Cancer Institute (NCI)
NCT01519817
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Astellas Pharma
NCT01409135
NP2 Enkephalin For Treatment of Intractable Cancer Pain
Diamyd
NCT01291901
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Eli Lilly and Company
NCT00207077
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
david andrews
NCT02507583
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors
INSYS Therapeutics
NCT00024661
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02897778
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Corcept Therapeutics
NCT05347979
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02909452
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
Baylor College of Medicine
NCT00042328
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
GlaxoSmithKline
NCT01966445
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
Boehringer Ingelheim
NCT00730821
An Open Label Study of Oral Enzastaurin in Participants With Cancer
Eli Lilly and Company
NCT00309140
A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
Genentech
NCT01986166
Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being
Connecticut Children's Medical Center
NCT02899117
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
R-Pharm
NCT00207090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 18 |
| Phase 3 | 7 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms page
160 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neoplasms trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms condition card totals 160 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.